News

Money Morning3d
Johnson & Johnson (JNJ) Is the Defensive Play to Make Amid Tariff Turmoil
There are, of course, risks to any investment, and Johnson & Johnson has them, too. The talc lawsuits are a wildcard and its ...
JNJ vs. PFE: Which Drug Giant is a Better Buy Now?
Johnson & Johnson JNJ and Pfizer PFE are two of the world’s largest pharmaceutical companies with diversified healthcare ...
24/7 Wall St. on MSN5d
4 Blue Chip Pharmaceutical High-Yield Dividend Stocks Are Tariff Winners
Large-cap pharmaceutical stocks like these may now be positioned to outperform as the impact of tariffs begins to take hold.
The Pharma Letter6h
NICE backing for J&J’s Balversa
The UK’s National Institute of Health and Care Excellence (NICE) has recommended erdafitinib, trade name Balversa and manufactured by Johnson & Johnson (NYSE: JNJ), for some adult patients in England.
Trump’s Next Tariffs Target Could Be Foreign-Made Medicines
President Trump wants to bring pharmaceutical manufacturing back to the United States. Experts warn that tariffs could result ...
S&P 500: Pharma Giants Lead Decline as Tariff Threats Rattle Pfizer, Merck, Johnson & Johnson
Pharmaceutical stocks tumble as Trump announces imminent “major tariff” on imported drugs. Pfizer, Merck, and Johnson & Johnson shares drop over 4%, dragging the broader S&P 500 lower.